Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q1

4583.TEDINET S100TEU8
Period2024-01-01 → 2024-03-31
Filed2024-05-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥130m2024-01-01 → 2024-03-31StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥169m2023-01-01 → 2023-03-31StandaloneNet sales
Operating income−¥322m2024-01-01 → 2024-03-31StandaloneOperating income
Operating income−¥226m2023-01-01 → 2023-03-31StandaloneOperating income
Ordinary income−¥303m2024-01-01 → 2024-03-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥227m2023-01-01 → 2023-03-31StandaloneOrdinary income
Profit before tax−¥303m2024-01-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax−¥226m2023-01-01 → 2023-03-31StandaloneIncome before income taxes
Net income−¥304m2024-01-01 → 2024-03-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥228m2023-01-01 → 2023-03-31StandaloneProfit loss
Total assets¥1.8bnat 2024-03-31StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥2.1bnat 2023-03-31StandaloneTotal assets (5-year summary)
Total liabilities¥506mat 2024-03-31StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2024-03-31StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.6bnat 2023-03-31StandaloneNet assets (5-year summary)
Cash and deposits¥1.3bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
EPS (basic)¥-5.62024-01-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.72023-01-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio70.4%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.3%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Shares issued55,720,600at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2023-03-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥133m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-03-31−¥246m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-03-31¥130m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-03-31¥130m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-03-31¥57m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-03-31¥130m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-03-31¥130m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-03-31−¥189m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥128m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-03-31−¥194m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-03-31¥96m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31−¥98m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 321
ItemContextValueUnit
Noncurrent assetsCurrentQuarterInstant_NonConsolidatedMember132886000JPY
AssetsPrior1YearInstant_NonConsolidatedMember1751454000JPY
AssetsCurrentQuarterInstant_NonConsolidatedMember1753934000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember37735000JPY
Accounts payable tradeCurrentQuarterInstant_NonConsolidatedMember38998000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember291000000JPY
Short term loans payableCurrentQuarterInstant_NonConsolidatedMember313600000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember116952000JPY
Accounts payable otherCurrentQuarterInstant_NonConsolidatedMember43036000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember25587000JPY
Accrued expensesCurrentQuarterInstant_NonConsolidatedMember24303000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember23952000JPY
Income taxes payableCurrentQuarterInstant_NonConsolidatedMember10481000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember31200000JPY
Advances receivedCurrentQuarterInstant_NonConsolidatedMember9100000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember5880000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember12045000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6730000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember－JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember539038000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember451566000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54692000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54799000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54692000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54799000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember593731000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember506366000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2388422000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember2587752000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3988202000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember4187532000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-5236350000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-5540374000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1139981000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1234618000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember17741000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember12949000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1157723000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1247567000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember1751454000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1753934000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember169404000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember129644000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember73464000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember72645000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember95940000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember56998000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember193637000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass